Kidney Effectiveness and Safety of Adding Spironolactone in Patients With Type 2 Diabetes Receiving Renin-Angiotensin System Inhibitors Therapy.

Although the increased risk of ESRD or renal transplantation did not reach statistical significance (HR = 1.32 [0.98–1.78]), the trend was consistent with our primary findings of worsened renal outcomes, including a sustained ≥ 30% decline in eGFR, with SL use.

also in 111,027 other papers

Importantly, heart failure status appeared to modify these associations: in patients with heart failure, add‐on spironolactone showed a trend toward a lower risk of ESRD/renal transplant, though the confidence interval crossed unity. 4.1 Reduced Proteinuria Risk While Increasing Adverse Renal Outcomes With the Use of SL Consistent with prior studies, our findings support the clinical effectiveness of SL in reducing proteinuria, a key surrogate marker of renal damage [ 4 , 8 , 9 , 10 , 23 , 24 ].

also in 53,322 other papers